Results 71 to 80 of about 5,988 (201)

Update on Direct Oral AntiCoagulants (DOACs)

, 2017
SummaryRecent findings require an update of previous recommendations for the perioperative use of Direct Oral AntiCoagulants (DOACs). A break in preoperative treatment of 24–96 hours is recommended based on the pharmacokinetic profiles of DOACs and ...
Christoph Rosenthal, Jürgen Koscielny, Christian von Heymann   +2 more
core   +1 more source

Very elderly patients with venous thromboembolism on oral anticoagulation with VKAs or DOACs: Results from the prospective multicenter START2-Register Study [PDF]

, 2019
Few data are available on the safety of anticoagulation in very elderly patients treated with Vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) for venous thromboembolism (VTE).Introduction: Few data are available on the safety of ...
Mastroiacovo, Daniela, Palareti, Gualtiero, Pastori, Daniele, Antonucci, Emilia, Testa, Sophie, Paparo, Carmelo, Poli, Daniela, Bertù, Lorenza, Vignini, Elisa, Ruocco, Lucia, Ageno, Walter   +10 more
core   +2 more sources

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +1 more source

Conducting clinical lactation trials in the United Kingdom—Reflections from the New Horizons clinical trial

British Journal of Clinical Pharmacology, EarlyView.
Jignesh P. Patel, Roopen Arya
wiley   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

European Journal of Haematology, EarlyView.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto, Silvia Sorella, Erminia Baldacci, Massimo Breccia, Sabina Chiaretti, Marcello Capriata, Livia Donzelli, Gianna Maria D'Elia, Salvatore Giacomo Morano, Ilaria Del Giudice, Maurizio Martelli, Cristina Santoro, Antonio Chistolini   +12 more
wiley   +1 more source

Healthcare Professionals' perspectives on prescribing DOACs to frail older patients; The DOAC-FRAIL questionnaire

BMC Geriatrics
Abstract Background DOACs are increasingly prescribed for atrial fibrillation and venous thromboembolism due to their ease of use and lack of monitoring requirements. Prescribing DOACs to frail older patients remains challenging due to higher bleeding and thrombo-embolic risks, comorbidities, polypharmacy, and underrepresentation in ...
de Jong, M.J., Brys, A.DH., Braeken, D., Pisters, R., Janssen, D.JA., Altintas, S., Robben, S.HM., Nicolai, S., Eurlings, C., Zwietering, A., De Jonghe, M., Vaes, B., De Backer, T., Grymonprez, M., Joosten, H., ten Cate, H., Winckers, K., Magdelijns, F.JH.   +17 more
openaire   +2 more sources

Do We Really Know How to Manage Anticoagulated Patients for Periodontal Nonsurgical Therapy? An Observational Cohort Study

International Journal of Dental Hygiene, EarlyView.
ABSTRACT Objectives The aim of this work is to assess and compare the impact of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKA) during and immediately after periodontal nonsurgical therapy. Materials and Methods A prospective observational cohort study was conducted with patients who presented a history of cardiovascular disease ...
F. Berton, A. Rapani, F. Costantinides, V. Nicolin, D. Cuhureanu, R. Di Lenarda   +5 more
wiley   +1 more source

Performance Assessment of Staclot‐LA Assay on Fully Automated Coagulation Analyser for Lupus Anticoagulant Testing Using Internal and External Quality Controls

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction It is recommended to detect lupus anticoagulant (LA) using two phospholipid‐dependent clotting assays, including a LA‐sensitive activated partial‐thromboplastin‐time (aPTT). Among these reagents, Staclot‐LA assay is performed on a mixture of test and normal plasma with and without hexagonal phase phospholipids.
V. Siguret, G. Jourdi, S. Melicine, L. Goubeau, Q. Pomorski, B. Joly‐Laffargue, A. Stepanian, M. Delrue, C. Bon, P. Meijer, E. Curis   +10 more
wiley   +1 more source

Refining Residual Ischemic Stroke Risk in Anticoagulated Atrial Fibrillation Using Index Outpatient LA Diameter: The CHA2DS2‐VALa Score

Journal of Cardiovascular Electrophysiology, EarlyView.
In anticoagulated atrial fibrillation, residual ischemic stroke risk persists despite guideline‐directed therapy. In this single‐center cohort, an enlarged index outpatient left atrial diameter independently predicted stroke and improved risk stratification when added to CHA2DS2‐VA (CHA2DS2‐VALa), supporting a simple, clinically implementable ...
Sefa Erdi Ömür, Emin Koyun, Gülşen Genç Tapar, Kayıhan Karaman, Metin Karayakali, Ataç Çelik, Uğur Kulu, Yasin Taşkin   +7 more
wiley   +1 more source

Optimal anticoagulation strategy for atrial fibrillation ablation: are all direct oral anticoagulants and vitamin K antagonists the same? - a meta-analysis of embolic and bleeding complications in more than 31,500 patients

Romanian Journal of Cardiology
The direct oral anticoagulants (DOACS) such as dabigatran (D), rivaroxaban (R), apixaban (A), and edoxaban (E) have become the leading anticoagulation strategy in atrial fibrillation (AF).
Musat Dan L, Enache Bogdan, Musat Alexandra, Bhatt Advay, Habibi Mohammadali, Kochav Stephanie, Sichrovsky Tina, Preminger Mark W, Mittal Suneet   +8 more
doaj   +1 more source